Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...

Secretary Robert F. Kennedy Jr. said he is considering a “regulatory framework” for Medicare and Medicaid to cover GLP-1 ...

Prescription weight loss medications, including GLP-1 agonists, orlistat, and Contrave, may be effective for some people. But other lifestyle changes are still necessary for long-term success.

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...

A major new study finds that certain diabetes medications, including GLP-1 and SGLT2 inhibitors, may be linked to a reduced ...

The effect of glucagon-like peptide 1 receptor agonists on patients with joint infections was a popular topic at the American ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

In general, these medications may also present cardiovascular risks, mental health effects, and drug interactions. The ...

Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First ...